News | October 09, 2024
Briefs: NATCO Pharma, Mylan Pharmaceuticals, Novo Nordisk and Alembic Pharmaceuticals
Mylan and Novo Nordisk reach settlement of US patent litigation related to Ozempic
Mylan and Novo Nordisk reach settlement of US patent litigation related to Ozempic
USFDA completes PAI of Lupin’s biotech facility in Pune
This facility underwent an inspection from 15th to 19th July 2024 and has been classified as Voluntary Action Indicated
The inspection conducted by EDQM at its Visakhapatnam facility
The observations are of procedural in nature and will be responded to within the stipulated time
Lupin's Pithampur Unit-1 gets Form 483 from USFDA with 3 observations
This approval reflects company’s unwavering commitment that the quality assurance
Glenmark Pharmaceuticals Limited has informed that the USFDA has issued Form 483 with zero observations
USFDA concludes inspection of Dr. Reddy's Laboratories R&D centre in Bachupally with zero observation
Fermenta Biotech’s API manufacturing facility receives EU GMP compliance certificate
Subscribe To Our Newsletter & Stay Updated
